DMB



DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 99N–0486]

Physician and Patient Labeling for Progestational Drug Products; Warnings and Contraindications

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is revoking its previously issued guidance texts for physician and patient labeling for progestational drug products that were published in the **Federal Register** of January 12, 1989 (54 FR 1243). A notice announcing FDA's intention to revoke these guidance texts was published in the **Federal Register** on April 13, 1999 (64 FR 18035). FDA received no comments on this notice. The guidance texts, which supplied physician and patient labeling for progestational drug products as a class, are no longer needed for the reasons discussed in the proposed rule on progestational drug products published in the **Federal Register** on April 13, 1999 (64 FR 17985). For additional information, see the final rule on progestational drug products that appears elsewhere in this issue of the **Federal Register**.

EFFECTIVE DATE: (*Insert date 1 year after date of publication in the* **Federal Register**.)

FOR FURTHER INFORMATION CONTACT: Diane V. Moore, Center for Drug Evaluation and Research (HFD–580), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–4260.

Dated: 11-4-99
November 4, 1999

CERTIFIED TO BE A TRUE COPY OF THE ORIGINAL

Margaret M. Dotzel
Acting Associate Commissioner
for Policy

[FR Doc. 99–???? Filed ??–??–99; 8:45 am]

BILLING CODE 4160–01–F